Melbourne, Australia; 28 February 2017 – Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP) is pleased to announce the appointment of existing nonexecutive director Dr Paul Wotton as Chairman of the Board of Directors. With Cynata now transitioning to a clinical stage company, the Board believes that Dr Wotton has the skills, focus and proven track record to help steer the Company effectively through this next stage of growth. Past chairman Dr Stewart Washer will remain on the Board as a non-executive Director. [Read more…]
Cynata Advances Development of Cymerus™ MSCs for the Treatment of Asthma
- Final report of initial preclinical study confirms Cymerus™ MSCs have significant beneficial effects on all three key components of asthma: airway hyper-responsiveness, inflammation and airway remodelling
- Additional preclinical study expected to pave the way for a potential clinical trial
Melbourne, Australia; 2 March 2017 – Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), has signed an agreement with the Monash Lung Biology Network, a consortia involving researchers from the Monash Biomedicine Discovery Institute and Department of Pharmacology at Monash University, Melbourne, to conduct a further preclinical study to support the use of CymerusTM mesenchymal stem cells (MSCs) for the treatment of asthma. [Read more…]
Luxcel, Axiogenesis, and BMG LABTECH Secure €2.5M for Cell Metabolism Analysis Platform
Luxcel Biosciences, Axiogenesis, and BMG LABTECH have announced €2.5M in funding to develop and launch a cell metabolism analysis platform, MetaCell™.
Together, these companies European technology subject matter experts (SMEs) have been awarded €2.5m funding from the European commission under the H2020 Fast Track to Innovation (FTI) pilot. The funding will support development of a cell metabolism analysis platform that aims to become integral to in vitro cell biology and drug development. [Read more…]
Treatment Benefit Confirmed in Final Report of GvHD Preclinical Study Using Cynata’s MSCs
-
Robust survival benefit resulting from treatment with CYP-001 confirmed
-
Substantial body of data generated to support mechanism of action of CYP-001 in GvHD
Melbourne, Australia; 6 February 2017 — Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced today that it has received a final report of the proof of concept study of its lead CymerusTM mesenchymal stem cell (MSC) product for graft-versus-host disease (GvHD), CYP-001, in a humanised mouse model of GvHD, which was conducted under the supervision of Associate Professor Lisa Minter at the University of Massachusetts Amherst (UMass), USA. [Read more…]
Axiogenesis Launches Cardio.Force, a Cardiac Contractile Force Assay Service
Axiogenesis, a worldwide leading provider of induced pluripotent stem cell (iPS cell) products, has added a vital new service offering: Cardio.Force, a technology for measuring the contractile force of the heart. This newest service offering includes assay services for iPSC-derived cardiomyocyte functionality and toxicity assessment.
In this article:
- The Cardio.Force Technology
- Cardio.Force’s Efficiency
- The Existing “Gold Standard” for Cardiac Force Assessment
- Cor.4CE Technology Overview
- Additional Advantages of the Cardio.Force Assay Service
Contractile Force of the Heart | Cardio.Force Service
The Cardio.Force Technology
Cardio.Force is based on the Axiogenesis’s 8-channel Cor.4CE assay device. Currently, 96 well versions are in development for an increased cardiac output and the reduction of cost per data point.
The utility of the technology was exemplified in a publication by Goßmann et al., “Mechano-Pharmacological Characterization of Cardiomyocytes Derived from Human Induced Pluripotent Stem Cells.” In the study, Goßmann concludes, “The measured data and simulations for pharmacologically unstimulated contraction resembled findings in native human heart tissue, while the pharmacological dose-response curves were highly accurate and consistent with reference data.”
Cardio.Force’s Efficiency
Such assay systems comprise the only cost-effective human in vitro technology that can measure the true cardiac contractile force of the heart. To date, common assay systems for quantitative measurement of contractility have been animal-based, which drive up cost and complexity. In contrast, the Cardio.Force assay offers an efficient system for pharmacological and toxicological studies using human cells that would otherwise require animal models or be more expensive/costly and with few cardiac outputs.
Cor.4U® human iPSC-derived cardiomyocytes are plated on extremely thin and highly flexible membranes for assessment of mechanobiological properties.
The Existing “Gold Standard” for Cardiac Force Assessment
Currently, the “Gold Standard” in toxicology and physiology has been isolated animal heart (Langendorff) preparations for contractility measurements. The Langendorff heart assay is a common in vitro approach used in pharmacological and physiological testing that allows cardiac contractile strength and heart rate to be determined without requiring an intact animal.[i] The major disadvantages of this system are that it is still an animal model, is expensive, is costing $5-20K per compound, is technically challenging, and has relatively high variability.
Other emerging technologies using iPSC-derived cardiomyocytes require very high numbers of cells creating microtissues that make the technology very expensive, while the Cor.4CE system requires only 300K cells per sample measurement.
The Cor.4CE system is also reproducible and scalable, which gives it further cost advantages.
Secondary readouts that are being championed/currently pursued for analyzing and assessing cardiac contractility include impedance measurements, atomic force measurements, movement, and calcium flux analysis. These systems fail to consistently correlate with clinical data; in contrast, the Cor.4CE system does show the expected results including a positive frequency force relationship in reaction to beta-adrenergic stimulation (e.g., isoproterenol) can be observed, proving true force measurement.
Cor.4CE Technology Overview
The Axiogenesis’s Cor.4CE device involves the culture of validated human iPSC-derived cardiomyocytes (Cor.4U) on flexible membranes for a more physiological system. The Axiogenesis Cor.4CE Analysis software allows for derivation of the true contractile force of the heart from the measurement of the displacement of the membrane generated by the contracting cardiomyocytes. It allows for repeatable contractility measurements with unprecedented accuracy under physiological mechanical conditions. Optionally, Cor.4U cardiomyocytes can be co-cultured with Cor.4U fibroblasts in order to increase the physiological relevance of the cell system.
Additional Advantages of the Cardio.Force Assay Service
- True force measurement in human iPSC-derived cardiomyocytes using proprietary Cor.4CE assay technology
- Highly precise, standardized, and repeatable test system in defined/controlled culture conditions
- Sensitive and predictive for cardiac safety pharmacology
- Suitable for scale-up given low compound volumes, quick turnaround
In summary, the combination of Cor.4U with the Cor.4CE system is the first in vitro assay setup to measure the true contractile force of the heart of iPSC-derived cardiomyocytes in a system suitable for scale-up. The system provides an ideal tool to assess pharmacological, safety pharmacological, and toxicological effects of drug candidates on human cardiomyocytes.
If you found this article valuable, subscribe to BioInformant’s stem cell industry updates.
We are the industry leaders in stem cell research, with research cited by The Wall Street Journal, Xconomy, AABB, and Vogue Magazine. Bringing you breaking news on an ongoing basis, join more than half a million loyal readers, including physicians, scientists, investors, and philanthropists.
What is your opinion about the Cardio.Force technology of Axiogenesis? Share your thoughts in the comments section below.
Up Next: Cynata’s iPSC-derived Cell Therapeutic (CYP-001) Meets Safety & Efficacy Endpoints
Footnote
[i] Bell, R., Mocanu, M. & Yellon, D. Retrograde heart perfusion: The Langendorff technique of isolated heart perfusion. Journal of Molecular and Cellular Cardiology 50, 940-950 (2011).
Editor’s Note: This post was originally published on February 1, 2017, and has been updated for quality and relevancy.
- « Previous Page
- 1
- …
- 42
- 43
- 44
- 45
- 46
- …
- 68
- Next Page »